for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pfizer Inc.

PFE.N

Latest Trade

35.48USD

Change

0.20(+0.57%)

Volume

7,454,210

Today's Range

34.84

 - 

35.53

52 Week Range

27.89

 - 

40.93

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
35.28
Open
35.21
Volume
7,454,210
3M AVG Volume
485.73
Today's High
35.53
Today's Low
34.84
52 Week High
40.93
52 Week Low
27.89
Shares Out (MIL)
5,556.88
Market Cap (MIL)
197,158.10
Forward P/E
--
Dividend (Yield %)
4.28

Next Event

Pfizer Inc Split For PFIZ34.SA - Ratio 4-1

Latest Developments

More

Mylan Says Combination With Upjohn Expected To Close On November 16

Pfizer Inc Reports Adjusted Earning Of $0.72 Per Share

FDA Grants Priority Review And EMA Accepts Regulatory Submission For Pfizer's Abrocitinib

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pfizer Inc.

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Industry

Biotechnology & Drugs

Contact Info

235 E 42ND ST

NEW YORK, NY

10017-5703

United States

+1.212.5732323

https://www.pfizer.com/

Executive Leadership

Albert Bourla

Chairman of the Board, Chief Executive Officer

John D. Young

Chief Business Officer, Group President

Frank A. D'Amelio

Chief Financial Officer, Executive Vice President - Business Operations and Global Supply

Angela Hwang

Group President, Pfizer Biopharmaceuticals Group

Dawn Rogers

Chief Human Resource Officer, Executive Vice President

Key Stats

2.58 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

52.5K

2018

53.6K

2019

51.8K

2020(E)

49.3K
EPS (USD)

2017

2.650

2018

3.000

2019

2.950

2020(E)

2.904
Price To Earnings (TTM)
23.85
Price To Sales (TTM)
4.05
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
15.00
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

U.S. approves combination of Pfizer's Upjohn and Mylan

The U.S. Federal Trade Commission said on Friday that it had approved generic drugmaker Mylan NV's <MYL.O> planned purchase of Pfizer's <PFE.N> Upjohn, subject to conditions.

UPDATE 1-UK starts accelerated reviews for COVID-19 vaccines from AstraZeneca and Pfizer - Bloomberg

Britain's health regulator has started accelerated reviews for COVID-19 vaccine candidates from Pfizer Inc and AstraZeneca Plc, according to a Bloomberg News report on Friday.

UK starts accelerated reviews for COVID-19 vaccines from AstraZeneca and Pfizer - Bloomberg

Britain's health regulator has started accelerated reviews for COVID-19 vaccine candidates from Pfizer Inc and AstraZeneca Plc, according to a Bloomberg report on Friday.

FACTBOX- The race for a coronavirus vaccine

(Adds Vaxart, updates AstraZeneca, Moderna, J&J, Bharat Biotech, Russia's vaccine) Oct 29 (Reuters) - Pfizer and German partner BioNTech, along with Moderna and AstraZeneca, are at the forefront in the race to successfully develop a safe and effective COVID-19 vaccine. There...

Britain expects verdict on Pfizer's COVID-19 vaccine before AstraZeneca's: Times

Senior sources in the British government expect that a verdict on whether Pfizer Inc-backed COVID-19 vaccine works will be available before the results are in on AstraZeneca Plc's competing vaccine, the Times reported.

Britain expects verdict on Pfizer's COVID-19 vaccine before AstraZeneca's -Times

Senior sources in the British government expect a verdict on whether Pfizer Inc and BioNTech SE's COVID-19 vaccine works will be available before AstraZeneca Plc's competing vaccine, the Times reported.

US STOCKS-S&P 500, Dow slip on earnings worries, stimulus uncertainty

* Indexes: Dow down 0.5%, S&P down 0.1%, Nasdaq up 0.5% (Updates to early afternoon)

Pfizer CEO: may be a week between conclusive vaccine data, public notification

Pfizer Inc's <PFE.N> Chief Executive Albert Bourla said on Tuesday that once it knows whether the vaccine candidate it is developing with Germany's BioNTech SE <22UAy.F> works, it could be a week before it lets the public know, making it unlikely it will release data before...

Pfizer says no COVID-19 vaccine data yet, could be week or more before it reports

Drugmaker Pfizer Inc <PFE.N> said on Tuesday it does not yet have data from the late-stage trial of the COVID-19 vaccine it is developing with Germany's BioNTech SE <22UAy.F>, and provided a timeline that makes its release unlikely ahead of the Nov. 3 U.S. presidential election.Pfizer...

US STOCKS-S&P 500, Dow slip on earnings worries, stimulus uncertainty

* Indexes: Dow down 0.28%, S&P down 0.03%, Nasdaq up 0.56% (Adds comment, details; updates prices)

Pfizer CEO: may be a week between conclusive vaccine data, public notification

Pfizer Inc's Chief Executive Albert Bourla said on Tuesday that once it knows whether the vaccine candidate it is developing with Germany's BioNTech SE works, it could be a week before it lets the public know, making it unlikely it will release data before the Nov. 3 presidential...

US STOCKS-S&P 500 flat after Monday's selloff as focus turns to corporate earnings

* Indexes: Dow down 0.26%, S&P flat, Nasdaq up 0.47% (Updates to market open)

Pfizer third-quarter sales fall 4.3% on pain drug weakness

Pfizer Inc on Tuesday reported a 4.3% drop in third-quarter sales, hurt by increased competition for its off-patent pain drug Lyrica and lower demand for some of its treatments during the COVID-19 pandemic.

U.S. likely to have enough COVID-19 vaccines for all vulnerable Americans by year end - official

The United States is likely to have enough safe and effective COVID-19 vaccines available to inoculate the most vulnerable Americans by the end of 2020, Health and Human Services Secretary Alex Azar said on Wednesday.

U.S. likely to have enough COVID-19 vaccines for all vulnerable Americans by year end -official

The United States is likely to have enough safe and effective COVID-19 vaccines available to inoculate the most vulnerable Americans by the end of 2020, Health and Human Services Secretary Alex Azar said on Wednesday.

Pfizer, BioNTech start combined trials of COVID-19 vaccine candidate in Japan

Pfizer Inc <PFE.N> and BioNTech SE announced on Tuesday the start in Japan of combined Phase I and Phase II clinical trials of their mRNA vaccine candidate against the coronavirus.

GLOBAL MARKETS-Asian markets jump on vaccine, U.S. aid hopes; China data caps gains

Asian markets advanced toward a recent 2-1/2-year peak on Monday powered by hopes of a U.S. fiscal package and expectations of a coronavirus vaccine by the end of this year, though gains were held back by weaker-than-expected Chinese economic data.

GLOBAL MARKETS-Asian markets jump on vaccine, U.S. aid hopes; gains capped by China data

Asian markets advanced toward a recent 2-1/2-year peak on Monday powered by hopes of a U.S fiscal package and expectations of a coronavirus vaccine by the end of this year, though weaker-than-expected Chinese data capped gains.

GLOBAL MARKETS-Asian markets start on firm footing on vaccine, U.S. aid hopes

Asian markets started higher on Monday, buoyed by hopes of a U.S fiscal package before the U.S. presidential elections next month and expectations of a coronavirus vaccine by the end of this year, though the mood was still cautious as infections jump.

Pfizer says earliest U.S. filing for COVID-19 vaccine would be late November

Pfizer Inc <PFE.N> said on Friday it could file in late November for U.S. authorization of the COVID-19 vaccine it is developing, suggesting that a vaccine could potentially be available in the United States by the end of the year.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up